Yesterday, Solid Biosciences issued a press release following receipt of written communication from the USA FDA regarding the clinical hold placed on their IGNITE DMD Phase I/II clinical trial. Please find below links to their press release and the corresponding letter they drafted to the Duchenne community.

Community Letter: https://www.solidbio.com/about/media/news/letter-to-the-duchenne-community-update-on-sgt-001-phase-i-ii-clinical-hold-for-ignite-dmd-program

Press Release:  https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-provides-update-regarding-sgt-001-phase-iii